Boehringer Ingelheim Reports Results of Cyltezo (biosimilar, adalimumab) in P-III

Shots: The P-III VOLTAIRE-X interchangeability study involves assessing the PK similarity, efficacy, immunogenicity, and safety profiles between patients with mod. to-sev. chronic PsO receiving Humira (40mg/0.8mL) continuously vs those who switched several times b/w Cyltezo and Humira Results: @32wks. the study met its 1EPs, supporting Cyltezo’s application as an interchangeable biosimilar to the reference product […]Read More